Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Candel Therapeutics, Inc. - Common Stock (NQ:CADL)

7.020 +0.020 (+0.29%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Candel Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
Candel Therapeutics Stock Rallies On Canaccord’s Vote Of Confidence In Lead Cancer Drug: Retail Traders Rejoice
CAN-2409 could become a “best-in-class therapy” for borderline resectable pancreatic ductal adenocarcinoma, according to the analyst. 
Via Stocktwits
This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
 
Via Benzinga
Candel Therapeutics Stock Headed For 20% Weekly Gains: Retail Over The Moon With BofA's 'Buy' Call
The analyst noted that CAN-2409's early data in prostate cancer suggests the potential for a meaningful breakthrough, given the lack of significant advancements in available treatments. 
Via Stocktwits
This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
 
Via Benzinga
Candel Therapeutics Provides Corporate Update and Highlights Strong Pipeline Momentum and Key Value Drivers for 2025
From Candel Therapeutics
Via GlobeNewswire
How Is The Market Feeling About Candel Therapeutics?
 
Via Benzinga
Why FedEx Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Candel Therapeutics Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
From Candel Therapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
What's Going On With Candel Therapeutics Shares Friday?
Candel shares are moving lower on Friday after the company priced its $80 million underwritten public offering of shares and pre-funded warrants. 
Via Benzinga
Candel Therapeutics, 8x8 And Other Big Stocks Moving Lower In Friday's Pre-Market Session
 
Via Benzinga
Why RH Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Candel Therapeutics Announces Pricing of Public Offering
From Candel Therapeutics
Via GlobeNewswire
Candel Therapeutics Announces $80 Million Proposed Public Offering
From Candel Therapeutics
Via GlobeNewswire
Candel Therapeutics Shares Are Up Today: What's Going On?
Candel Therapeutics, Inc. (NASDAQ: CADL) shares are trading higher Thursday potentially driven by continued momentum following the company's announcement of positive phase 3 trial results for its... 
Via Benzinga
Gamestop, Adobe, Meta, Candel Therapeutics, And Tesla: Why These 5 Stocks Are On Investors' Radars Today
The stock market experienced a wave of optimism on Wednesday, driven by the latest inflation report. The Nasdaq 100 surged 1.7%, achieving a new record high. 
Via Benzinga
Topics Economy
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Crude Oil Jumps 2%; Macy's Lowers Earnings Forecast
 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Nasdaq Surges Over 1%; US Inflation Rises In-Line With Expectations
 
Via Benzinga
Topics Economy
Candel Therapeutics Stock Surges Over 100% - Here's Why
Candel Therapeutics reports phase 3 trial success for CAN-2409 in prostate cancer, showing improved disease-free survival and safety consistency. 
Via Benzinga
Candel Skyrockets By Triple Digits On A Potential First-In-20-Years Cancer Drug
The company is hoping to eventually launch the first major new treatment for localized prostate cancer in over 20 years. 
Via Investor's Business Daily
Candel Therapeutics Announces CAN-2409 Achieved Primary Endpoint in Phase 3 Prostate Cancer Trial, Showing Significantly Improved Disease-Free Survival
From Candel Therapeutics
Via GlobeNewswire
Candel Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
From Candel Therapeutics
Via GlobeNewswire
Candel Therapeutics to Present at Jefferies London Healthcare Conference 2024
From Candel Therapeutics
Via GlobeNewswire
Candel Therapeutics to Present Preclinical Data at SITC Annual Meeting Showing Promise for CAN-3110 in Melanoma, Signaling Potential Indication Expansion Beyond Recurrent High-Grade Glioma
From Candel Therapeutics
Via GlobeNewswire
Candel Therapeutics Showcases Innovative Cancer Therapy Candidates at 16th Annual International Oncolytic Virotherapy Conference (IOVC)
From Candel Therapeutics
Via GlobeNewswire
Candel Therapeutics to Present Preclinical Data on Therapeutic Potential of CAN-3110 in Melanoma at SITC 2024 Annual Meeting
From Candel Therapeutics
Via GlobeNewswire
Candel Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
From Candel Therapeutics
Via GlobeNewswire
CADL Stock Earnings: Candel Therapeutics Reported Results for Q2 2024
Candel Therapeutics just reported results for the second quarter of 2024. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS